Lack of Association between the Pro12Ala Polymorphism in PPAR-γ2 Gene and Body Weight Changes, Insulin Resistance and Chronic Diabetic Complications in Obese Patients with Type 2 Diabetes

Archives of Medical Research

Volumn 37, Issue 6, 2006, Pages 736-743

  Stefanski, Adam ^a   Majkowska, Liliana ^a   Ciechanowicz, Andrzej ^a   Frankow, Miroslaw ^a   Safranow, Krzysztof ^a   Parczewski, Milosz ^a   Pilarska, Krystyna ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Diabetic complications; PPAR ; Pro12Ala polymorphism; Type 2 diabetes

Indexed keywords

ALANINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROLINE;

ADULT; ALLELE; ANAMNESIS; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL EXAMINATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; WEIGHT CHANGE;

AGED; BODY WEIGHT; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; RISK FACTORS;

EID: 33745677651     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2006.01.009     Document Type: Article

References (40)

1. De Fronzo R.A. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 5 (1997) 177-285
2. Rieusset J., Andreelli F., Auboeuf D., Roques M., Vallier P., Riou J.P., et al. Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor-gamma in human adipocytes. Diabetes 48 (1999) 699-705
3. Fajas L., Auboeuf D., Raspe E., Schoonjans K., Lefebvre A.M., Saladin R., et al. Organization, promoter analysis and expression of the human PPARγ gene. J Biol Chem 272 (1997) 18779-18789
4. Fajas L., Fruchart J.C., and Auwerx J. PPARγ3 mRNA; a distinct PPARγ mRNA subtype transcribed from an independent promoter. FEBS Lett 438 (1998) 55-60
5. Werman A., Hollenberg A., Solanes G., Bjorbaek C., Vidal-Puig A.J., and Flier J.S. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPAR gamma). Differential activity of PPAR gamma-1 and -2 isoforms and influence of insulin. J Biol Chem 272 (1998) 20230-20235
6. Yen C.J., Beamer B.A., Negri C., Silver K., Brown K.A., Yarnall D.P., et al. Molecular scanning of the human peroxisome proliferator-activated receptor γ (PPARγ) gene in diabetic Caucasians: identification of a Prol12Ala PPAR γ2 missense mutation. Biochem Biophys Res Commun 240 (1997) 270-274
7. Altshuler D., Hirschhorn J.N., Klannemark M., Lindgren C.M., Vohl M.C., Nemesh J., et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26 (2000) 76-80
8. Deeb S., Fajas L., Nemoto M., Laakso M., Fujimoto W., and Auwerx J. A Pro12 Ala substitution in the human peroxisome proliferator-activated receptor gamma2 is associated with decreased receptor activity, improved insulin sensitivity, and lowered body mass index. Nat Genet 20 (1998) 284-287
9. Koch M., Rett K., Maerker E., Volk A., Haist K., Deninger M., et al. The PPARγ2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of type 2 diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. Diabetologia 42 (1999) 758-762
10. Beamer B.A., Yen C.J., Andersen R.E., Muller D., Elahi D., Cheskin L.J., et al. Association of the Pro12Ala variant in peroxisome proliferator-activated receptor gamma2 gene with obesity in two Caucasian populations. Diabetes 47 (1998) 1806-1808
11. Ek J., Urhammer S.A., Sorensen T.I.A., Andersen T., Auwerx J., and Pedersen O. Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor γ2 (PPAR-γ2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 42 (1999) 892-895
12. Gurnell M., Savage D.B., Chatterjee V.K.K., and O'Rahilly S. The metabolic syndrome: peroxisome proliferator-activated receptor γ and its therapeutic modulation. J Clin Endocrinol Metab 88 (2003) 2412-2421
13. Hara K., Okada T., Tobe K., Yasuda K., Mori Y., Kadowaki H., et al. The Pro12Ala polymorphism in PPAR-gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 271 (2000) 212-216
14. Jacob S., Stumvoll M., Becker R., Koch M., Nielsen M., Loblein K., et al. The PPARgamma2 polymorphism Pro12Ala is associated with better insulin sensitivity in the offspring of type 2 diabetic patients. Horm Metab Res 32 (2000) 413-416
15. Ek J., Andersen G., Urhammer S.A., Hansen L.A., Carstensen B., Borch-Johnsen K., et al. Studies of the Pro12Ala polymorphism of the perioxisome proliferator-activated receptor-γ2 (PPAR-γ2) gene in relation to insulin sensitivity among glucose tolerant Caucasians. Diabetologia 44 (2001) 1170-1176
16. Delerive P., Martin-Nizard F., Chinetti G., Trottein F., Fruchart J.C., Najib J., et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 85 (1999) 394-402
17. 12Ala genotype of the peroxisome proliferator-activated receptor-γ 2 protects against atherosclerosis. J Clin Endocrinol Metab 89 (2004) 4238-4242
18. Ridker P.M., Cook N.R., Cheng S., Erlich H.A., Lindpaintner K., Plutzky J., et al. Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol 23 (2003) 859-863
19. Caramori M.L., Canani L.H., Costa L.A., and Gross J.L. The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes 52 (2003) 3010-3013
20. Herrmann S.M., Ringel J., Wang J.G., Staessen J.A., and Brand E. Berlin Diabetes Mellitus (BeDiaM) Study. Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study. Diabetes 51 (2002) 2653-2657
21. Wallace T.M., Levy J.C., and Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 27 (2004) 1487-1495
22. Malecki M.T., Frey J., Klupa T., Skupien J., Walus M., Mlynarski W., et al. The Pro12Ala polymorphism of PPARgamma2 gene and susceptibility to type 2 diabetes mellitus in a Polish population. Diabetes Res Clin Pract 62 (2003) 105-111
23. Pihlajamaki J., Vanhala M., Vanhala P., and Laakso M. The Pro12Ala polymorphism of the PPAR gamma 2 gene regulates weight from birth to adulthood. Obes Res 12 (2004) 187-190
24. Kao W.H., Coresh J., Shuldiner A.R., Boerwinkle E., Bray M.S., and Brancati F.L. Atherosclerosis Risk in Communities Study. Pro12Ala of the peroxisome proliferator-activated receptor-gamma2 gene is associated with lower serum insulin levels in nonobese African Americans: the Atherosclerosis Risk in Communities Study. Diabetes 52 (2003) 1568-1572
25. Douglas J.A., and Erdos M.R. The peroxisome proliferator-activated receptor-γ2 Pro12Ala variant. Association with type 2 diabetes and trait differences. Diabetes 50 (2001) 886-890
26. Makimattila S., Nikkila K., and Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia 42 (1999) 406-412
27. Wolever T.M., Chiasson J.L., Josse R.G., Hunt J.A., Palmason C., Rodger N.W., et al. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. Int J Obes Relat Metab Disord 21 (1997) 756-763
28. Parulkar A.A., Pendergrass M.L., Granda-Ayala R., Lee T.R., and Fonseca V.A. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 134 (2001) 61-71
29. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
30. Yamamoto J., Kageyama S., Nemoto M., Sasaki T., Sakurai T., Ishibashi K., et al. PPARgamma2 Pro12Ala polymorphism and insulin resistance in Japanese hypertensive patients. Hypertens Res 25 (2002) 25-29
31. Bluher M., and Paschke R. Analysis of the relationship between PPAR-gamma 2 gene variants and severe insulin resistance in obese patients with impaired glucose. Exp Clin Endocrinol Diabetes 111 (2003) 85-90
32. Rosmond R., Chagnon M., and Bouchard C. The Pro12Ala PPARgamma2 gene missense mutation is associated with obesity and insulin resistance in Swedish middle-aged men. Diabetes Metab Res Rev 19 (2003) 159-163
33. Li S., Chen W., Srinivasan S.R., Boerwinkle E., and Berenson G.S. The Bogalusa Heart Study. The peroxisome proliferator-activated receptor-gamma2 gene polymorphism (Pro12Ala) beneficially influences insulin resistance and its tracking from childhood to adulthood: the Bogalusa Heart Study. Diabetes 52 (2003) 1265-1269
34. Kahara T., Takamura T., Hayakawa T., Nagai Y., Yamaguchi H., Katsuki T., et al. PPARgamma gene polymorphism is associated with exercise-mediated changes of insulin resistance in healthy men. Metabolism 52 (2003) 209-212
35. Ostergard T., Ek J., Hamid Y., Saltin B., Pedersen O.B., Hansen T., et al. Influence of the PPAR-gamma2 Pro12Ala and ACE I/D polymorphisms on insulin sensitivity and training effects in healthy offspring of type 2 diabetic subjects. Horm Metab Res 37 2 (2005) 99-105
36. Lindi V.I., Uusitupa M.I., Lindstrom J., Louheranta A., Eriksson J.G., Valle T.T., et al. Finnish Diabetes Prevention Study. Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 51 8 (2002) 2581-2586
37. Guan Y., Zhang Y., Schneider A., Davis L., Breyer R.M., and Breyer M.D. Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature. Am J Physiol Renal Physiol 281 (2001) F1036-F1046
38. Asano T., Wakisaka M., Yoshinari M., Iino K., Sonoki K., Iwase M., et al. Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation. Biochim Biophys Acta 1497 (2000) 148-154
39. Iijima K., Yoshizumi M., Ako J., Eto M., Kim S., Hashimoto M., et al. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in rat aortic smooth muscle cells. Biochem Biophys Res Commun 247 (1998) 353-356
40. Florez J.C. Phenotypic consequences of the peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism: the weight of the evidence in genetic association studies. J Clin Endocrinol Metab 89 (2004) 4234-4237